Rovi Extends Product and Entertainment Discovery Patent License Agreement to Funai
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Harry and Meghan surprised by King Charles' letter on their status
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- S&P 500 falls as AI worries hit software makers
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Brean Capital Cuts Price Target on Rovi Corp. (ROVI) to $20 Following 2Q15 Results
July 31, 2015 8:55 AM EDTBrean Capital maintained a Buy rating on Rovi Corp. (NASDAQ: ROVI), a cut the price target to $20.00 (from $31.00), following 2Q15 results. Rovi reported 2Q15 revenue of $128 million and EPS of $0.38. Management lowered its full year guidance for revenue to $500 million to $530 million, from $535 million to $565 million, and for non-GAAP EPS to $1.35 to $1.60, from $1.55 from $1.85.
Analyst Todd Mitchell... More
